MEDI-0457 is a DNA Vaccine owned by AstraZeneca, and is involved in 17 clinical trials, of which 9 were completed, and 8 are ongoing.
MEDI0457 (INO-3112) is a combination of DNA plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, with DNA plasmid encoding human interleukin-12 (IL-12). HPV DNA plasmids therapeutic vaccine expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. E6 and E7 proteins are oncogenes that cause transformations in cells that can eventually cause these cells to become cancerous. DNA Plasmid expresses IL-12 and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells.
The revenue for MEDI-0457 is expected to reach a total of $154m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the MEDI-0457 NPV Report.
MEDI-0457 (VGX-3100 plus DNA-based IL-12 cytokine) is under development for the treatment of HPV-caused head and neck squamous cell carcinoma (HNSCC), HPV positive oropharyngeal squamous cell carcinoma, cervical cancer, vulvar cancer, anal, penile cancer and vaginal cancer, newly diagnosed glioblastoma. It is administered intramuscularly by electroporation. INO-3112 is DNA-based combination immunotherapeutic composed of VGX-3100 DNA plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18 combined with INO-9012, a DNA plasmid encoding interleukin-12 (IL-12). The vaccine is developed based on SynCon DNA vaccine technology, ASPIRE technology and CELLECTRA electroporation-based delivery technology. It was also under development for advanced unresectable or metastatic urothelial carcinoma.
Inovio Pharmaceuticals Overview
Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; INO-3107 for recurrent respiratory papillomatosis (RRP); and INO-5151 for prostate cancer. The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
The company reported revenues of (US Dollars) US$1.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 76% over FY2020. The operating loss of the company was US$301.2 million in FY2021, compared to an operating loss of US$119.4 million in FY2020. The net loss of the company was US$303.7 million in FY2021, compared to a net loss of US$166.4 million in FY2020. The company reported revenues of US$9.2 million for the third quarter ended September 2022, compared to a revenue of US$0.8 million the previous quarter.
Quick View – MEDI-0457
|Highest Development Stage|